WHO CNS5 2021 classification of gliomas: a practical review and road signs for diagnosing pathologists and proper patho-clinical and neuro-oncological cooperation
- PMID: 35950467
- DOI: 10.5114/fn.2022.118183
WHO CNS5 2021 classification of gliomas: a practical review and road signs for diagnosing pathologists and proper patho-clinical and neuro-oncological cooperation
Abstract
The 5th edition of World Health Organization (WHO) Central Nervous System (CNS) tumours classification has transformed the pathological diagnosis of gliomas from purely histological to the multilayered integrated one with molecular biomarkers necessary for proper classification, risk stratification, and prognostic-predictive clinical purposes. Because of deep and important changes in taxonomy and diagnostic approach to gliomas, this manuscript is a review of WHO CNS classification 5th edition with general testing guidance for pathologists and clinicians working in neuro-oncology.
Keywords: 5th edition; WHO; classification; neuropathology; gliomas.
Similar articles
-
What Changed in CNS5? A Mini-Review on General Changes and Adult Diffuse Gliomas.Ann Afr Med. 2024 Jul 1;23(3):255-261. doi: 10.4103/aam.aam_63_23. Epub 2024 Jul 20. Ann Afr Med. 2024. PMID: 39034544 Free PMC article. Review.
-
Updates on the WHO diagnosis of IDH-mutant glioma.J Neurooncol. 2023 May;162(3):461-469. doi: 10.1007/s11060-023-04250-5. Epub 2023 Jan 30. J Neurooncol. 2023. PMID: 36717507 Free PMC article. Review.
-
[The 2021 WHO Classification of Tumors, 5th edition, Central Nervous System Tumors: A Short Review].Brain Nerve. 2022 Jun;74(6):803-809. doi: 10.11477/mf.1416202124. Brain Nerve. 2022. PMID: 35676215 Review. Japanese.
-
Classification and Grading of Central Nervous System Tumors According to the World Health Organization 5th Edition.Semin Neurol. 2023 Dec;43(6):833-844. doi: 10.1055/s-0043-1776793. Epub 2023 Nov 10. Semin Neurol. 2023. PMID: 37949117
-
Clinical Laboratory Testing Practices in Diffuse Gliomas Prior to Publication of 2021 World Health Organization Classification of Central Nervous System Tumors.Arch Pathol Lab Med. 2022 May 1;147(5):518-524. doi: 10.5858/arpa.2021-0431-CP. Arch Pathol Lab Med. 2022. PMID: 35878398
Cited by
-
Pediatric-type diffuse high-grade glioma with systemic metastasis: A case report.Neurooncol Adv. 2025 Apr 3;7(1):vdaf069. doi: 10.1093/noajnl/vdaf069. eCollection 2025 Jan-Dec. Neurooncol Adv. 2025. PMID: 40351828 Free PMC article. No abstract available.
-
Uses of artificial intelligence in glioma: A systematic review.Med Int (Lond). 2024 May 20;4(4):40. doi: 10.3892/mi.2024.164. eCollection 2024 Jul-Aug. Med Int (Lond). 2024. PMID: 38827949 Free PMC article.
-
Dietary Polyphenols: Luteolin, Quercetin, and Apigenin as Potential Therapeutic Agents in the Treatment of Gliomas.Nutrients. 2025 Jul 1;17(13):2202. doi: 10.3390/nu17132202. Nutrients. 2025. PMID: 40647306 Free PMC article. Review.
-
microRNAs (miRNAs) in Glioblastoma Multiforme (GBM)-Recent Literature Review.Int J Mol Sci. 2023 Feb 9;24(4):3521. doi: 10.3390/ijms24043521. Int J Mol Sci. 2023. PMID: 36834933 Free PMC article. Review.
-
Recapitulating the Key Advances in the Diagnosis and Prognosis of High-Grade Gliomas: Second Half of 2021 Update.Int J Mol Sci. 2023 Mar 28;24(7):6375. doi: 10.3390/ijms24076375. Int J Mol Sci. 2023. PMID: 37047356 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical